Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 3 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A
4(80.0%)
Phase 1
1(20.0%)
5Total
N/A(4)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT02029885Not ApplicableUnknown

Sham Controlled Study of Renal Denervation for Subjects With Uncontrolled Hypertension

Role: lead

NCT02480517Not ApplicableUnknown

Sham Controlled Study of Renal Denervation for Untreated Stage I and II Hypertension

Role: lead

NCT01926951Not ApplicableCompleted

Renal Denervation Using Externally Focused Therapeutic Ultrasound

Role: lead

NCT01704170Not ApplicableCompleted

Feasibility Study to Evaluate Renal Denervation Using Focused Ultrasound

Role: lead

NCT01638195Phase 1Completed

A Safety Evaluation of Renal Denervation Using Focused Therapeutic Ultrasound on Patients With Refractory Hypertension

Role: lead

All 5 trials loaded